Boston Scientific account plan
global medical technology leader
At a glance
Boston Scientific develops and sells medical devices for cardiovascular, GI, urology and neuromodulation care in 127 countries; FY2025 sales $20,074 million.
Boston Scientific, headquartered in Marlborough, Massachusetts, develops, manufactures and markets mostly single-use medical devices for less-invasive treatment of cardiovascular, respiratory, digestive, oncological, neurological and urological diseases. It sells to hospitals, clinics, outpatient facilities and medical offices in 127 countries, with large group purchasing organizations and hospital networks a substantial portion of sales. FY2025 net sales were $20,074 million (+19.9% reported, +15.8% organic) and GAAP net income attributable to common stockholders $2,898 million. It had approximately 59,000 employees at 31 December 2025, approximately 60 percent outside the U.S.
Business units
Interventional Cardiology and Vascular Therapies (ICVT)
about 23.1% of FY2025 sales ($4,639 million)Coronary, peripheral and venous technologies including SYNERGY stents, the AGENT drug-coated balloon, IVUS imaging and thrombectomy. Q2 2026 sales were $1,333 million, and management expects ICVT to become its strongest growth driver; Penumbra will join it once the acquisition closes.
Electrophysiology
about 16.6% of FY2025 sales ($3,325 million)FARAPULSE pulsed field ablation for atrial fibrillation plus mapping and access tools; sales rose from $1,904 million in 2024. Q2 2026 EP grew 9% but U.S. growth slowed to 3% on competitive share movement, and H2 2026 global EP is guided flat.
Cardiac Rhythm Management (CRM)
about 11.6% of FY2025 sales ($2,332 million)Implantable defibrillators, pacemakers, LATITUDE remote monitoring and LUX-Dx insertable cardiac monitors. Q2 2026 sales were $585 million, down slightly; a new defibrillator platform is due in H2 2027.
WATCHMAN
about 9.8% of FY2025 sales ($1,958 million)Left atrial appendage closure devices for non-valvular AF patients at risk of stroke, heavily U.S.-based. Q2 2026 growth slowed to 4% as standalone U.S. procedures declined, and management expects 2027 to be difficult with a new competitor.
Interventional Oncology and Embolization (IO&E)
about 5.0% of FY2025 sales ($996 million)TheraSphere Y-90 microspheres for liver cancer, cryoablation and embolization coils; Intera Oncology was acquired in Q2 2025. Q2 2026 sales were $283 million, up 12%.
Endoscopy
about 14.5% of FY2025 sales ($2,916 million)Devices for gastrointestinal and pancreaticobiliary conditions and weight loss, including AXIOS stents, SpyGlass and EXALT single-use scopes. Q2 2026 sales were $793 million, +7.0% organic, led by the biliary franchise.
Urology
about 13.5% of FY2025 sales ($2,709 million)Kidney stone, BPH, prostate cancer, incontinence and sacral neuromodulation devices, including Axonics. Q2 2026 sales rose only 0.8% organically on volume-based procurement in China and disruption in sacral neuromodulation; three stone launches are planned.
Neuromodulation
about 6.0% of FY2025 sales ($1,199 million)Spinal cord and deep brain stimulation and the Intracept system for vertebrogenic pain; Nalu Medical was acquired on 27 January 2026. Q2 2026 sales were $341 million, +12.2% organic.
Strategic priorities
- Five strategic imperatives
- Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities.
- Launch pipeline for 2028
- Management lists seven new launches exceeding about a $25 billion TAM in 2028, including coronary IVL (H1 2027), TIVUS renal denervation, Penumbra, ICE imaging, FARAWAVE Ultra, the potential MiRus TAVR acquisition and circulatory support.
- Recovering EP and WATCHMAN growth
- The company is investing in physician education, commercial coverage and direct-to-patient programmes for WATCHMAN, and plans FARAWAVE Ultra and ICE entry in H2 2027 and FARAFLEX in 2028 for EP.
- New operating structure
- From 1 January 2027 three reportable segments (Interventional Therapies, Rhythm Solutions and MedSurg) replace the current two, under new COO Joseph M. Fitzgerald, to enable faster decision making.
- Cost savings to reinvest in growth
- The 2026 Restructuring Plan targets about $500 million a year of gross pre-tax savings by end-2029, with a substantial portion reinvested in growth initiatives.
Latest results
In Q2 2026 (quarter ended 30 June 2026) net sales were $5,442 million, +7.5% reported and +7.0% organic, and adjusted EPS was $0.86 (+14.6%); gross margin rose to 70.7%. Growth came mainly from ICVT and Electrophysiology, while increased EP competition and slower WATCHMAN procedures held sales back. On 29 July 2026 the company cut its full-year 2026 guidance to 5% to 6% organic growth and adjusted EPS of $3.28 to $3.32. A cybersecurity incident identified on 25 August 2026 then disrupted manufacturing and order shipping globally, and the company said it is unlikely to meet its Q3 and full-year guidance.
Investments and deals
- Penumbra acquisition
- Agreed on 15 January 2026 at $374 per share, approximately $14.500 billion, adding computer-assisted vacuum thrombectomy; stockholders approved it on 6 May 2026 and closing is expected in the second half of 2026 subject to regulatory clearance.
- MiRus TAVR option
- A $1.500 billion payment on 15 May 2026 bought about 33.75% of MiRus LLC, with an exclusive option to buy its SIEGEL TAVR business for a further $3.000 billion once milestones are met.
- Tuck-in acquisitions
- Bolt Medical, SoniVie, Cortex and Intera were acquired in 2025 ($1.593 billion), and Nalu Medical in January 2026 for approximately $517 million.
- 2026 Restructuring Plan
- Approved on 21 July 2026: supply chain optimization including production line transfers and functional transformation, with $700-800 million of pre-tax charges through end-2029.
- Share repurchases
- The buyback authorization was raised to $5.000 billion and a $2.000 billion accelerated repurchase retired about 40 million shares.
Challenges and risks
- Cybersecurity incident
- Unauthorized activity identified on 25 August 2026 caused a global network outage that hit manufacturing, order processing and shipping; the timeline for full recovery was uncertain at the 8-K filing.
- Competition in pulsed field ablation
- Management did not anticipate the degree of competitive share movement in U.S. EP, where PFA is approximately 80% of the AFib market.
- WATCHMAN referral slowdown
- Clinical evidence from trials such as OCEAN and CLOSURE has reduced referrals for standalone procedures, with a new competitor expected in 2027.
- Pricing and procurement pressure
- Health care consolidation, national tenders and volume-based procurement in China weigh on pricing, notably in stone management.
- Tariffs and supply chain
- The company cites tariff uncertainty, higher distribution costs, single-source components and sterilization capacity as risks.
What leadership says
“This update today is not the outcome we planned or what you've come to expect from us.”
“In 2025, we achieved over $20 billion in sales and for the second year in a row, delivered mid-teens growth”
“These changes reflect the scale and breadth of our business today and the opportunities ahead.”
Where a supplier can help
- Cyber resilience and IT recovery
- The August 2026 cybersecurity incident that halted manufacturing and shipping makes security, OT protection, backup and recovery offers directly relevant.
- Supply chain and manufacturing transfers
- The 2026 Restructuring Plan's production line transfers and supply chain optimization create needs for validation, automation and logistics partners.
- Penumbra integration
- Integrating a roughly $14.500 billion acquisition into the new Interventional Therapies segment calls for systems, sales operations and change management support.
- Physician education and patient demand
- The WATCHMAN response relies on physician education and direct-to-patient investment, which suits medical education, digital marketing and patient engagement providers.
- Clinical trial execution
- A pipeline resting on trials such as FARADIGM, SIMPLIFY and STAR fits CRO, imaging core lab and trial technology services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Boston Scientific?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- Boston Scientific is a global maker of less-invasive medical devices: FY2025 net sales $20,074 million (+19.9% reported, +15.8% organic), about 59,000 employees, sales in 127 countries; 36% of sales international.
- Two segments: Cardiovascular $13,250 million (about 66% of sales, computed; +20.8% organic) and MedSurg $6,824 million (about 34%; +6.7% organic), each with a segment operating margin of about 32-33%.
- Largest units: Interventional Cardiology & Vascular Therapies $4,639 million, Electrophysiology $3,325 million (up from $1,904 million on FARAPULSE pulsed field ablation), Endoscopy $2,916 million, Urology $2,709 million, CRM $2,332 million, WATCHMAN $1,958 million.
- Adjusted EPS $3.06 (+21.9%); GAAP net income $2,898 million; gross margin 69.0%; R&D $2,052 million (10.2% of sales); operating cash flow $4,534 million.
- Acquisitive: Bolt Medical, SoniVie, Intera in 2025; Nalu Medical closed January 2026 (about $517 million); Penumbra agreed January 2026 for about $14.500 billion, about $11.000 billion of it in cash and new debt.
- Five strategic imperatives: category leadership, high-growth adjacencies, global expansion (emerging markets $2,985 million), funding the journey, key capabilities.
- Key risks: competition (including domestic players in China), pricing and tender pressure, tariffs, single-source supply and sterilization, cyber-attacks on IT/OT systems, acquisition integration, EU MDR.
- ACURATE TAVR valves discontinued in 2025; litigation charge of $194 million for a legacy IP matter.
- Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 net sales $5,442 million, +7.5% reported and +7.0% organic; H1 net sales $10,646 million, +8.1% organic.
- Q2 adjusted EPS $0.86 (+14.6%), GAAP EPS $0.61. Gross margin was 70.7%, helped by the recovery of previously paid tariffs.
- Cardiovascular $3,624 million (+7.8% organic): AGENT drug-coated balloon and FARAPULSE drove growth, but the 10-Q cites "increased competition within our Electrophysiology business unit" and slowing WATCHMAN procedures.
- MedSurg $1,818 million (+5.4% organic): Neuromodulation +12.2% (Intracept, Nalu) and Endoscopy +7.0% (AXIOS), while Urology rose only 0.8% (China volume-based procurement, sacral neuromodulation disruption).
- Penumbra (about $14.500 billion) is under an FTC Second Request and expected to close in H2 2026; a $2.000 billion 364-day revolver and a $6.000 billion term loan can be drawn only at closing.
- $1.500 billion invested for about 33.75% of MiRus, with a $3.000 billion option to buy its SIEGEL TAVR business, a route back into TAVR.
- $2.000 billion accelerated buyback completed (about 40 million shares); buyback authorization raised to $5.000 billion.
- New 2026 Restructuring Plan: $700-800 million of charges through 2029, about $500 million of annual savings, some headcount reductions; savings largely reinvested in growth.
- Q2 2026 earnings call transcript
- Q2 2026 organic sales +7% and adjusted EPS of 86 cents (+15%), but full-year guidance was cut to 5-6% organic growth and $3.28-3.32 adjusted EPS; Q3 guided to +3-5%.
- Mahoney: "This update today is not the outcome we planned or what you've come to expect from us"; the cut is "concentrated in two areas", WATCHMAN and EP.
- WATCHMAN: the U.S. LAAC market "slowed sharply and unexpectedly" as new trial evidence changed referral patterns; H2 global decline of mid to high single digits, and a competitor is expected in 2027.
- EP: the company under-called U.S. PFA share loss to competitors; H2 global EP flat. Recovery is tied to FARAWAVE Ultra and ICE in H2 2027 and FARAFLEX in 2028.
- The rest of the business, "roughly 75% of our revenue", should grow about 6% in H2; Neuromodulation, ICVT and IO&E each grew 12% in Q2, Urology 1% and CRM -2%.
- 2027: revenue growth below WAMGR (now "seven to eight") and "limited adjusted EPS growth"; strong EPS growth targeted again from 2028.
- Seven launches with "about a $25 billion TAM" by 2028: IVL, hypertension renal denervation, Penumbra, ICE, FARAWAVE Ultra, MiRus TAVR, circulatory support.
- New restructuring targets about $500 million of savings, over half by exit-2027, landing in S&A before COGS.
- Q4 2025 earnings call transcript
- FY2025: over $20 billion of sales, 16% organic growth, adjusted EPS $3.06 (+22%), adjusted operating margin 28.0%, free cash flow $3.659 billion.
- Original 2026 guidance: 10-11% organic growth and adjusted EPS $3.43-3.49 (+12-14%); long-range '26 to '28 targets of 10%-plus growth and 150 bps margin expansion reaffirmed.
- EP grew 73% in 2025 on FARAPULSE; about 70% of U.S. AF ablations now use PFA; market seen growing about 15% in 2026, with some share loss expected from a "65-ish percent" PFA share.
- WATCHMAN grew 29% in Q4; Stein said "we have not seen any impact" from the OCEAN and CLOSURE trials. CHAMPION could widen eligible patients from about 5 million to 20 million.
- New ICVT unit combines peripheral vascular (Cat Jennings) with interventional cardiology; AGENT DCB drives over 20% growth in drug-eluting technology; coronary IVL expected H1 2027.
- Urology was the weak spot (5% organic) after Axonics integration and supply issues; AXIOS product removal weighs on H1 2026 Endoscopy.
- M&A first, then buybacks: Penumbra (thrombectomy, PE, neurovascular), Nalu (closed), Valencia (pending).
- Form 8-K: material cybersecurity incident update (Item 1.05)
- Cybersecurity incident identified 25 August 2026: unauthorized activity caused a network outage and "a global disruption to the Company's operations", hitting manufacturing, order processing and shipping.
- By the 8 September filing, major distribution centers were shipping "at or above normal operating levels", sterilization was operational and manufacturing had resumed at most sites; the full recovery timeline was uncertain.
- The company says it is "unlikely to meet" its 29 July net sales growth and adjusted EPS guidance for Q3 and full year 2026.
- It expects to recover part of the lost revenue as backlogs clear and sees no material impact on long-term financial condition.
- An updated 2026 outlook will come with Q3 results on 28 October 2026; no evidence of ongoing unauthorized access had been found and the investigation continues.
- Press release: Joseph M. Fitzgerald named COO, three new reportable segments from 2027
- From 1 January 2027 Joseph M. Fitzgerald (now group president, Cardiovascular) becomes EVP and COO, overseeing global operations, business units and regions.
- Three new reportable segments replace MedSurg/Cardiovascular: Interventional Therapies, Rhythm Solutions and MedSurg.
- Interventional Therapies (Lance Bates): Interventional Cardiology, Vascular Therapies, Interventional Oncology & Embolization, and Penumbra after closing.
- Rhythm Solutions (Nick Spadea-Anello): Electrophysiology, WATCHMAN, Cardiac Rhythm Management & Diagnostics.
- MedSurg (Stephen Morse, also president Asia Pacific): Endoscopy, Urology, Neuromodulation.
- Mahoney: the model "will create greater capacity to focus on our long-term growth priorities while enabling our businesses to move faster".
Questions about Boston Scientific
What does Boston Scientific do?
Boston Scientific develops, manufactures and markets medical devices, mostly single-use, for less-invasive treatment of cardiovascular, digestive, urological, neurological, oncological and respiratory conditions.
What was Boston Scientific's revenue in 2025?
Net sales were $20,074 million in FY2025, up 19.9% reported and 15.8% organic, with adjusted EPS of $3.06.
How many employees does Boston Scientific have?
Approximately 59,000 employees at 31 December 2025, approximately 60 percent outside the U.S.
Who leads Boston Scientific?
Mike Mahoney is Chairman and CEO and Jonathan Monson is CFO; Joseph M. Fitzgerald becomes Chief Operating Officer on 1 January 2027.
What is Boston Scientific's growth strategy?
It combines internal R&D with acquisitions such as Penumbra and Nalu, targets high-growth adjacencies and global expansion, and plans seven major launches by 2028.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)